The Japanese pharmaceutical market is the second largest individual market and with sales of $60 billion constitutes approximately 11% of the world market. However, it is a market that frustrates the major pharmaceutical companies as it is growing at a significantly lower rate of growth than the average of the world pharmaceutical markets.
Historically this has been attributed to the struggling Japanese economy, but more recently the biennial NHI drug price reductions have been the determining factor of the Japanese pharmaceutical market. As the Japanese government seeks to stimulate further industrial growth, it must adopt policies that also continue to restrict the overall health expenditure.
Table of Contents
1. Executive Summary
1.1 Japanese Pharmaceutical Market Set for Low Growth but Considerable Change
1.2 Aims, Scope and Format
1.3 Research Methodology
2 Introduction
2.1 Japan Remains a Key Market for Pharmaceuticals
2.2 The Japanese Drug Regulatory Authorities
2.3 The Pharmaceutical Affairs Law (PAL) has been important in shaping the Japanese Drugs Market
2.4 Acronyms
3. A Brief Insight into the Japanese Economy and Culture of Business
3.1 Features of the Most Developed Eastern Country
3.2 Current Situation of the Japanese Economy, 1995-2005
4. An Overview of the Japanese Pharmaceutical Market
4.1 Japan's Place in the World Pharmaceutical Market
4.2 Cardiovascular Treatments Dominate Japanese Pharmaceutical Market
4.3 The Japanese Wholesale Industry Has Shown No Growth and High Consolidation
4.4 Drivers and Restraints for the Japanese Pharmaceutical Market
4.4.1 Drivers
4.4.2 Restraints
4.5 Changes in the Japanese Approval System
4.6 CNS and Cancer Treatments are Therapeutic Growth Areas
4.7 Reliance on Revenues from the Japanese Market Only is a Weakness
4.8 Forecasts for the Japanese Pharmaceutical Market
5. Top Ten Japanese Pharmaceutical Companies
5.1 Further Pharmaceutical Consolidation Expected
5.1.1 Takeda Pharmaceutical Co - Background
5.1.2 Takeda Leads Japanese Market with 5.2% Market Share
5.1.3 Rozerem, Takeda's New Sleep Disorder Treatment
5.1.4 Actos Provides Growth for TPNA
5.1.5 Takeda Increases its R&D Investment
5.1.6 Takeda Acquire Biotech Company
5.1.7 Takeda's Range of Products Drives Success
5.1.8 Increased R&D Investment Enhances Takeda's Pipeline
5.2 Astellas Pharma Inc - A Merger of Two Complementary Companies
5.2.1 Astellas' Merger Results in Large Product Portfolio
5.2.2 Complementary Regional Revenue Streams for Astellas
5.2.3 Astellas and Co-marketing Agreements
5.2.4 R & D - The Way Forward for Future Success
5.2.5 Key Financials
5.2.6 Pipeline Products Through Co-development
5.3 Daiichi Sanko Co. Background to the Latest Merger
5.3.1 Six Key Areas of Therapeutic Research
5.3.2 Product Portfolios are Complementary
5.3.3 Daiichi Sankyo Begins Merger With OTC Products
5.3.4 Daiichi Launch Adenoscan - A Japanese First
5.3.5 Daiichi Sankyo Co-promotion Agreement with UCB
5.3.6 Diagnostic Products Remain Important
5.3.7 Increased Independence - Sanofi-Aventis Dissolve Agreements
5.3.8 Daiichi Sankyo Divest Non-Core Business
5.3.9 Combined Financial Strength is Key for Future
5.3.10 Limited Pipeline With Low US Focus
5.4 Other Japanese Pharmaceutical Companies
5.4.1 Eisai Dissolves Agreement With Sanofi-Aventis
5.4.2 Eisai Strengthens Alzheimer's Knowledge
5.4.3 US Market Presence is Key for Eisai
5.4.4 European Market is Also Important for Eisai
5.4.5 Is Dainippon Sumitomo Pharma Too Unfocused?
5.4.6 Dainippon Sumitomo Continues Investment into Diabetes
5.4.7 Chugai and Roche - The First Major Japanese/Global Merger
5.4.8 Mitsubishi Pharma - a Conglomerate With Potential Financial Backing
5.4.9 Kyowa Hakko Kogyo - Focused But Risky Strategy
5.4.10 Shionogi Launches New Antibiotics
5.5 Leading Pharmaceutical Products in Japan
5.6 Summary: Japanese Companies Will Have Limited Futures
6. Global Pharmaceutical Companies in Japan
6.1 Global Pharmaceutical Companies Increase Presence in Japan
6.2 Pfizer Merger Increases Pfizer's Presence in Japan
6.2.1 COPD - A Key Area of Interest for Pfizer
6.3 Roche Initiates Global Presence in Japan
6.4 Novartis Continues to Divest
6.5 Merck Struggles in Japan
6.6 GSK Reorganises Its Medical Sales Force
6.7 Summary
7. The Japanese Patent System
7.1 A Patent System of Constant Change
7.2 An Improved Patent System Encourages R&D
7.3 US Patent System Determining Japanese R&D
7.4 Patent Licensing for Genetic Material is Becoming More Important
7.5 Changes in Approval Times Will Aid Non-Domestic Companies' Entry into the Japanese Pharmaceutical Market
7.6 Summary
8. Pricing and Reimbursement in Japan
8.1 The Japanese Healthcare System
8.2 Revisions to the Health Insurance Law Saw an Increase in Co-Pay
8.3 Japanese Drug Pricing
8.4 New Developments:
8.5 New Drug Approval and License System Will Cut Drug Approval Time
8.6 The Japanese Reference System
8.7 The Reexamination and Reevaluation Drug Systems are Used to Predict Drug Safety
8.8 Japan Has Reduced Healthcare Spending Including Drugs
8.9 Generic Drug Prices are Set at 70% of the Original Drug Price
8.10 Generic Substitution in Japan
8.11 The Japanese Wholesale Market in Consolidation
8.12 Bungyo: the Separation of Dispensing and Prescribing is Rapidly Increasing
8.13 Bungyo Separation Has Dramatic Effect on Retail Pharmacies
8.14 Conclusion: The Japanese Government Directly Controls Drug Prices through Price Cuts
9. Generic Pharmaceuticals in Japan
9.1 Generic Drugs Have Low Japanese Market Share
9.2 The Key Reason for Low Generic Adoption is Financial
9.3 Other Obstacles to Generics in Japan
9.4 What is the Japanese Government Doing to Increase Generic Usage?
9.5 Leading Generic Companies Merge - Further Mergers Predicted
10. Conclusion
10.1 Japanese Pharmaceutical Market Set for Low Growth but Considerable Change
For more information, Please visit :
http://www.bharatbook.com/
